SCHEMBL305388

SCHEMBL305388

CC(C)(C)OC(=O)N1CCSC(CO)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.50
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.39
PREP P48147 1/20 0.38
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
EPHX2 P34913 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
GPR119 Q8TDV5 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31616175 0.87 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL3489113 0.87 NR1H2 (0.42) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL14242316 0.87 NR1H2 (0.42) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL5190564 0.85 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL5149626 0.84 NR1H2 (0.53) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL29283753 0.81 NR1H2 (0.38) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL9668776 0.81 NR1H2 (0.38) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL160579 0.77 USP2 (0.42) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL27189660 0.76 USP2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL14242317 0.76 USP2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492197-B2 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof Impact Therapeutics (Shanghai), Inc (CN) 2025-12-09 US disclosed
US-20220356181-A1 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-11-10 US disclosed
US-20150031674-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-01-29 US disclosed
US-20150031674-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-01-29 US disclosed
WO-2015011252-A1 PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-01-29 WO disclosed
US-20150031674-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-01-29 US disclosed
WO-2015011252-A1 PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-01-29 WO disclosed
US-8093244-B2 Heteroaryl urea derivatives useful for inhibiting CHK1 ICOS CORPORATION (US) 2012-01-10 US disclosed
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 US disclosed
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 US disclosed
EP-2330105-A1 Heteroaryl urea derivatives useful for inhibiting CHK1 ICOS Corporation (US) 2011-06-08 EP disclosed
US-20100056523-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION 2010-03-04 US disclosed
US-7625890-B2 Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors SMITHKLINE BEECHAM CORP. (US) 2009-12-01 US disclosed
US-20090143357-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 ICOS CORPORATION (US) 2009-06-04 US disclosed
US-20080076763-A1 Inhibitors of Akt activity GLAXOSMITHKLINE LLC 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356181-A1 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF CHEK1, CHEK2, CDK2 NR1H2 3440/4885MAPT 4427/4885MEN1 2822/4885
US-12492197-B2 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof CHEK1, CHEK2, CCNK NR1H2 3014/4885MAPT 4523/4885MEN1 2942/4885
US-20150031674-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 NR1H2 2948/4885MAPT 1138/4885MEN1 1307/4885
US-20080076763-A1 Inhibitors of Akt activity PI4KB, PIK3CA, AKT2 NR1H2 4137/4885MAPT 3969/4885MEN1 3151/4885
US-20100056523-A1 INHIBITORS OF AKT ACTIVITY PI4KB, PIK3CA, AKT2 NR1H2 4137/4885MAPT 3969/4885MEN1 3151/4885
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS PRKCZ, PRKCQ, PRKCD NR1H2 3250/4885MAPT 927/4885MEN1 4292/4885
US-20090143357-A1 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 CHEK1, CHEK2, PCNA NR1H2 2917/4885MAPT 2615/4885MEN1 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.